AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22551775 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 9
Study 20685721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency treatment
Number of subjects: 40
Study 20685721 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcutaneous electrical nerve stimulation treatment
Number of subjects: 40
Study 18595903 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme
Number of subjects: 457
Study 18595903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 457
Study 15293416 — intervention group
Group type: EXPERIMENTAL
Intervention: Uno (Pulpdent)
Number of subjects: 18
Study 15293416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PBNT, Dentsply Caulk)
Number of subjects: 18
Study 15293416 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB, 3M ESPE)
Number of subjects: 18
Study 11506214 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 102
Study 11506214 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 102
Study 11506214 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training
Number of subjects: 102
Study 11506214 — intervention group
Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 102
Study 9686709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific information on prognoses and specially trained nurse to facilitate decision making
Number of subjects: 14
Study 7517256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gammaglobulin (50 mg/kg daily in four divided doses for 28 days)
Number of subjects: 72
Study 7517256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 2560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (estrone sulfate) at a dose of 1.25 mg/day for 6 weeks
Number of subjects: 7
Study 2560521 — intervention group
Group type: COMPARATOR
Intervention: Untreated women with SDAT
Number of subjects: 7
Study 918793 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rebreathing (semiclosed) circuit enflurane anaesthesia
Number of subjects: 0
Study 918793 — intervention group
Group type: COMPARATOR
Intervention: Vaporizer out of circle (VOC) rebreathing system
Number of subjects: 0
Study 918793 — intervention group
Group type: COMPARATOR
Intervention: Vaporizer in circle (VIC) system
Number of subjects: 0
Study 30355445 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (100 µg po)
Number of subjects: 24
Study 30355445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + LSD
Number of subjects: 24
Study 30355445 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 24
Study 26780757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging with low-molecular-weight heparin during interruption of vitamin K antagonists
Number of subjects: 0
Study 26780757 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual peri-interventional management based on risk profile
Number of subjects: 0
Study 24118931 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily premixed protamine-aspart/aspart insulin (PM-2)
Number of subjects: 588
Study 24118931 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin glargine plus zero to one prandial insulin glulisine injection (G+1)
Number of subjects: 588
Study 24118931 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus zero to three prandial injections (G+3)
Number of subjects: 588
Study 22420675 — intervention group
Group type: EXPERIMENTAL
Intervention: professionally facilitated peer group intervention for HIV prevention
Number of subjects: 400
Study 19841158 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140, 280, 560, or 700 mg every 8 hours for 7 days)
Number of subjects: 32
Study 19841158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18289823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stigma printed materials (Reading Group, RG)
Number of subjects: 193
Study 18289823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stigma computer program (Program Group, PG)
Number of subjects: 193
Study 18289823 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group, CG)
Number of subjects: 193
Study 16163900 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucophage mite (Germany)
Number of subjects: 24
Study 16163900 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucophage mite (France)
Number of subjects: 24
Study 12913100 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (30 Gy IF + 10 Gy to bulky disease)
Number of subjects: 1204
Study 12913100 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy (30 Gy EF + 10 Gy to bulky disease)
Number of subjects: 1204
Study 11061613 — intervention group
Group type: EXPERIMENTAL
Intervention: CV6504, 100 mg TDS, orally for three months
Number of subjects: 31
Study 8771625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis training
Number of subjects: 35
Study 8771625 — intervention group
Group type: COMPARATOR
Intervention: No explicit training in stress-reduction strategies (Control)
Number of subjects: 35
Study 1617044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg twice daily)
Number of subjects: 3
Study 1617044 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily)
Number of subjects: 3
Study 1617044 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (500 mg twice daily)
Number of subjects: 3
Study 1617044 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg/125 mg three times daily)
Number of subjects: 3
Study 1617044 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 3
Study 6143188 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (5 exchanges in 10 days, 55 ml plasma/kg body weight/exchange)
Number of subjects: 30
Study 6143188 — intervention group
Group type: COMPARATOR
Intervention: Normal supportive care
Number of subjects: 30
Study 31772092 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection from the Labour Inspection Authority
Number of subjects: 0
Study 31772092 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance through an online interactive risk-assessment tool
Number of subjects: 0
Study 31772092 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on psychosocial, organisational and mechanical work environment through workshops
Number of subjects: 0
Study 31772092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 29290066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanning behaviors (indoor tanning, concurrent tanning types)
Number of subjects: 818
Study 27011355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 23
Study 27011355 — intervention group
Group type: COMPARATOR
Intervention: Relaxation programme
Number of subjects: 23
Study 24408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 80
Study 24408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 80
Study 24408116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23173253 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage combined Chinese materia medica (CMM) footbath fumigation and washing
Number of subjects: 61
Study 23173253 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of meloxicam
Number of subjects: 61
Study 23173253 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage combined CMM footbath fumigation and washing
Number of subjects: 61
Study 20405136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula
Number of subjects: 6209
Study 20405136 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 6209
Study 20405136 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor breast milk
Number of subjects: 6209
Study 20405136 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-IgE-mediated cow's milk allergy)
Number of subjects: 6209
Study 17922170 — intervention group
Group type: EXPERIMENTAL
Intervention: Searching tutorial (up to 6 1-hour small group sessions)
Number of subjects: 0
Study 17922170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tutorial)
Number of subjects: 0
Study 16034238 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser deepithelization
Number of subjects: 12
Study 16034238 — intervention group
Group type: COMPARATOR
Intervention: Scalpel deepithelization
Number of subjects: 12
Study 12061947 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomotor threshold (CMT) in ALS patients with disease duration < 6 months (Group A)
Number of subjects: 25
Study 12061947 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomotor threshold (CMT) in ALS patients with disease duration > 24 months (Group B)
Number of subjects: 25
Study 12061947 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 25
Study 12061947 — intervention group
Group type: EXPERIMENTAL
Intervention: M-wave amplitude in ALS patients (Group A and Group B)
Number of subjects: 25
Study 12061947 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT correlation with disease duration
Number of subjects: 25
Study 10192829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 302
Study 10192829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 302
Study 10192829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 7798511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline (selective antagonist of A1 adenosine receptors)
Number of subjects: 34
Study 7798511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7798511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline
Number of subjects: 34
Study 3674851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (500 or 250 mg twice daily) for 7 days
Number of subjects: 0
Study 3674851 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (250 mg three times daily)
Number of subjects: 0
Study 29090846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg plus laser (COMBI)
Number of subjects: 128
Study 29090846 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy (LASER)
Number of subjects: 128
Study 26652026 — intervention group
Group type: EXPERIMENTAL
Intervention: MD2011001 cream
Number of subjects: 44
Study 26652026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25109413 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1070806 (0.008 - 10 mg/kg)
Number of subjects: 0
Study 25109413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23543663 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 89
Study 23543663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 89
Study 23543663 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D₃ supplements (Control)
Number of subjects: 89
Study 20525742 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) using the GALS screening tool for MSS examination
Number of subjects: 209
Study 20525742 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) for trainees
Number of subjects: 209
Study 20525742 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard MSS training)
Number of subjects: 209
Study 20525742 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees (PAL)
Number of subjects: 209
Study 20525742 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainers (PAL)
Number of subjects: 209
Study 18707870 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (8 cycles)
Number of subjects: 1921
Study 18707870 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (6 cycles)
Number of subjects: 1921
Study 18707870 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Number of subjects: 1921
Study 18707870 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 1921
Study 19787287 — intervention group
Group type: EXPERIMENTAL
Intervention: PCD therapy
Number of subjects: 81
Study 19787287 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 81
Study 19787287 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 81
Study 16386096 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing using the A1cNow device
Number of subjects: 7758
Study 16386096 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory analysis using ion exchange high-performance liquid chromatography
Number of subjects: 7758
Study 11561116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 53
Study 11561116 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg daily)
Number of subjects: 53
Study 11561116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) in females with primary Raynaud's phenomenon
Number of subjects: 53
Study 11561116 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg daily) in females with primary Raynaud's phenomenon
Number of subjects: 53
Study 9115059 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (10 mg/mL)
Number of subjects: 6
Study 9115059 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine (2 mg/mL)
Number of subjects: 6
Study 9115059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.2 mg/mL)
Number of subjects: 6
Study 9115059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 mg/mL)
Number of subjects: 6
Study 9115059 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (1 microgram/mL)
Number of subjects: 6
Study 9115059 — intervention group
Group type: EXPERIMENTAL
Intervention: All vasodilators
Number of subjects: 6
Study 7964960 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron 8 mg
Number of subjects: 20
Study 7964960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 4 mg
Number of subjects: 6
Study 3034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 6
Study 3034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 6
Study 3034469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day for 15 days
Number of subjects: 6
Study 11487547 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40
Study 11487547 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 40
Study 31404469 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy (OMTh) for 3 months
Number of subjects: 20
Study 31404469 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline for 3 months
Number of subjects: 20
Study 29987329 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 μg/min over 20 minutes)
Number of subjects: 32
Study 29987329 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 32
Study 29987329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26871700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 41
Study 26871700 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (TA) 4 mg
Number of subjects: 41
Study 25072617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-3 N(t)RTI + LPV/r
Number of subjects: 210
Study 25072617 — intervention group
Group type: COMPARATOR
Intervention: RAL + LPV/r
Number of subjects: 210
Study 23006898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (stress doses)
Number of subjects: 111
Study 23006898 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 2-AG levels
Number of subjects: 111
Study 23006898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandamide and 2-AG levels during the perioperative period
Number of subjects: 111
Study 23006898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 20391211 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchoring heuristic
Number of subjects: 468
Study 20391211 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability heuristic
Number of subjects: 468
Study 20391211 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 468
Study 17266687 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.3 mg) administered via continuous intravenous infusion for 6 hours, starting 1 hour before ERCP, with additional subcutaneous injections of 0.1 mg at 6 and 12 hours after infusion stopped.
Number of subjects: 832
Study 17266687 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously.
Number of subjects: 832
Study 15483639 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea bread (CHB)
Number of subjects: 12
Study 15483639 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded chickpea bread (EXB)
Number of subjects: 12
Study 15483639 — intervention group
Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 12
Study 11752033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of 3D-Gadolinium MR angiography (3D-Gd-MRA) and cine phase-contrast flow measurement (PC-flow)
Number of subjects: 43
Study 11752033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Gadolinium MR angiography (3D-Gd-MRA)
Number of subjects: 43
Study 11752033 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 43
Study 9469172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral pain management program
Number of subjects: 22
Study 9469172 — intervention group
Group type: COMPARATOR
Intervention: Attention/support control treatment
Number of subjects: 22
Study 8593922 — intervention group
Group type: EXPERIMENTAL
Intervention: Des(64,65)-proinsulin (DPRO) at doses of 0.1, 0.15, 0.2 U/kg
Number of subjects: 9
Study 8593922 — intervention group
Group type: COMPARATOR
Intervention: NPH-insulin at doses of 0.2, 0.3, 0.4 U/kg
Number of subjects: 9
Study 8593922 — intervention group
Group type: EXPERIMENTAL
Intervention: Des(64,65)-proinsulin (DPRO)
Number of subjects: 9
Study 2664509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 22071
Study 2664509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 1115339 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 8165, 1 times 25 mg/kg
Number of subjects: 240
Study 1115339 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium, 1 mg/kg
Number of subjects: 240
Study 31832912 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety promotion intervention (n=91)
Number of subjects: 277
Study 31832912 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (n=186)
Number of subjects: 277
Study 31511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple education program focusing on coparenting, consisting of two interactive classes and a short video.
Number of subjects: 21
Study 31511452 — intervention group
Group type: COMPARATOR
Intervention: Standard childbirth education classes (control group).
Number of subjects: 21
Study 28679142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IU of vitamin D
Number of subjects: 90
Study 28679142 — intervention group
Group type: COMPARATOR
Intervention: 1,000 IU of vitamin D
Number of subjects: 90
Study 28679142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25497244 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (transitioning to VKA)
Number of subjects: 13397
Study 25497244 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (continuing on VKA)
Number of subjects: 13397
Study 25497244 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (for warfarin-naive patients)
Number of subjects: 13397
Study 23381685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive‐behavioral therapy intervention (up to 18 weeks)
Number of subjects: 0
Study 22180523 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r + RAL
Number of subjects: 206
Study 22180523 — intervention group
Group type: COMPARATOR
Intervention: LPV/r + TDF/FTC
Number of subjects: 206
Study 19658033 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions offered in the parent clinical trial
Number of subjects: 68
Study 19658033 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 68
Study 19658033 — intervention group
Group type: EXPERIMENTAL
Intervention: History of violent impulses and arrest
Number of subjects: 68
Study 19658033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment received
Number of subjects: 68
Study 19658033 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 68
Study 16372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 500 mg
Number of subjects: 39
Study 16372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 250 mg
Number of subjects: 39
Study 16372352 — intervention group
Group type: COMPARATOR
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT)
Number of subjects: 39
Study 16372352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 14526711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture; details on dosage and duration not available.
Number of subjects: 0
Study 14526711 — intervention group
Group type: COMPARATOR
Intervention: Control groups; details not specified.
Number of subjects: 0
Study 10539706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spira Elektro 4 jet nebulizer with budesonide (0.5 mg)
Number of subjects: 10